$SSKN
STRATA Skin Sciences, Inc.

2024 Q1 Form 10-K Financial Statement

#000114036124015754 Filed on March 28, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $6.754M $8.689M $33.36M
YoY Change -10.74% -18.04% -7.75%
Cost Of Revenue $3.674M $3.888M $14.90M
YoY Change 15.57% 3.57% 3.5%
Gross Profit $3.080M $4.801M $18.46M
YoY Change -29.81% -29.89% -15.19%
Gross Profit Margin 45.6% 55.25% 55.34%
Selling, General & Admin $5.728M $5.578M $23.46M
YoY Change -13.98% -11.08% -7.58%
% of Gross Profit 185.97% 116.18% 127.1%
Research & Development $241.0K $380.0K $1.317M
YoY Change -23.49% -13.83% 27.99%
% of Gross Profit 7.82% 7.92% 7.13%
Depreciation & Amortization $1.249M $3.434M $5.553M
YoY Change 84.49% -1.24% 131.38%
% of Gross Profit 40.55% 71.53% 30.08%
Operating Expenses $5.969M $5.958M $24.78M
YoY Change -14.41% -11.26% -6.19%
Operating Profit -$2.889M -$1.157M -$6.320M
YoY Change 11.72% -963.43% 35.94%
Interest Expense $524.0K -$445.0K -$1.409M
YoY Change 83.22% 92.64% -252.16%
% of Operating Profit
Other Income/Expense, Net -$479.0K -$2.318M
YoY Change 92.37% 176.94%
Pretax Income -$3.368M -$3.886M -$10.92M
YoY Change 18.8% 3906.19% 99.09%
Income Tax $0.00 -$92.00K -$92.00K
% Of Pretax Income
Net Earnings -$3.368M -$3.794M -$10.83M
YoY Change 18.8% 2271.25% 95.17%
Net Earnings / Revenue -49.87% -43.66% -32.47%
Basic Earnings Per Share -$0.10 -$0.31
Diluted Earnings Per Share -$0.10 -$0.11 -$0.31
COMMON SHARES
Basic Shares Outstanding 35.06M 35.05M 34.92M
Diluted Shares Outstanding 35.06M 34.92M

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $5.237M $6.784M $6.784M
YoY Change 85.38% 24.84% 24.84%
Cash & Equivalents $5.237M $6.784M $6.784M
Short-Term Investments
Other Short-Term Assets $1.677M $1.646M $1.646M
YoY Change -18.27% -19.79% -19.79%
Inventory $2.695M $2.673M $2.673M
Prepaid Expenses
Receivables $3.630M $4.440M $4.440M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $13.24M $15.54M $15.54M
YoY Change -8.77% -11.2% -11.2%
LONG-TERM ASSETS
Property, Plant & Equipment $11.73M $12.40M $12.40M
YoY Change 43.31% 65.43% 46.39%
Goodwill $6.519M $6.519M
YoY Change -25.95% -25.95%
Intangibles $6.825M $7.319M
YoY Change -59.07% -57.92%
Long-Term Investments
YoY Change
Other Assets $231.0K $231.0K $231.0K
YoY Change 181.71% 135.71% 135.71%
Total Long-Term Assets $26.81M $26.47M $26.47M
YoY Change -22.54% -23.86% -23.86%
TOTAL ASSETS
Total Short-Term Assets $13.24M $15.54M $15.54M
Total Long-Term Assets $26.81M $26.47M $26.47M
Total Assets $40.05M $42.02M $42.02M
YoY Change -18.47% -19.62% -19.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.592M $3.343M $3.343M
YoY Change 15.91% -2.39% -2.39%
Accrued Expenses $6.269M $6.658M $6.658M
YoY Change -4.28% 1.57% -3.65%
Deferred Revenue $2.366M $2.120M
YoY Change -7.14% -23.69%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $12.59M $12.17M $12.17M
YoY Change -3.6% -9.33% -9.33%
LONG-TERM LIABILITIES
Long-Term Debt $15.08M $15.04M $15.04M
YoY Change 100.55% 101.23% 101.23%
Other Long-Term Liabilities $2.767M $1.924M $1.924M
YoY Change -68.98% -79.16% -79.16%
Total Long-Term Liabilities $15.08M $16.97M $16.97M
YoY Change 100.55% 126.97% 1.55%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.59M $12.17M $12.17M
Total Long-Term Liabilities $15.08M $16.97M $16.97M
Total Liabilities $30.62M $29.33M $29.33M
YoY Change 2.73% -3.66% -3.66%
SHAREHOLDERS EQUITY
Retained Earnings -$241.4M -$238.1M
YoY Change 4.94% 4.77%
Common Stock $35.00K $35.00K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $9.432M $12.69M $12.69M
YoY Change
Total Liabilities & Shareholders Equity $40.05M $42.02M $42.02M
YoY Change -18.47% -19.62% -19.62%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$3.368M -$3.794M -$10.83M
YoY Change 18.8% 2271.25% 95.17%
Depreciation, Depletion And Amortization $1.249M $3.434M $5.553M
YoY Change 84.49% -1.24% 131.38%
Cash From Operating Activities -$804.0K $1.506M -$519.0K
YoY Change -33.17% -30220.0% -53.16%
INVESTING ACTIVITIES
Capital Expenditures $725.0K $1.853M $5.019M
YoY Change -48.44% 22.31% 41.3%
Acquisitions $0.00
YoY Change -100.0%
Other Investing Activities $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities -$725.0K -$1.853M -$5.019M
YoY Change -48.44% 22.31% 19.99%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -18.00K 0.000 6.861M
YoY Change -100.0% -1472.2%
NET CHANGE
Cash From Operating Activities -804.0K 1.506M -519.0K
Cash From Investing Activities -725.0K -1.853M -5.019M
Cash From Financing Activities -18.00K 0.000 6.861M
Net Change In Cash -1.547M -347.0K 1.323M
YoY Change -40.71% -82.82% -122.85%
FREE CASH FLOW
Cash From Operating Activities -$804.0K $1.506M -$519.0K
Capital Expenditures $725.0K $1.853M $5.019M
Free Cash Flow -$1.529M -$347.0K -$5.538M
YoY Change -41.4% -77.17% 18.84%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
691000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
15543000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
15052000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11778000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9950000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
626000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
975000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
7319000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
17394000
CY2023Q4 us-gaap Goodwill
Goodwill
6519000
CY2022Q4 us-gaap Goodwill
Goodwill
8803000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5434000
CY2023Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
1334000
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
1361000
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
222000
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
382000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4471000
CY2023Q4 us-gaap Inventory Net
InventoryNet
2673000
CY2022Q4 us-gaap Inventory Net
InventoryNet
3095000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
98000
CY2023Q4 us-gaap Assets
Assets
42016000
CY2022Q4 us-gaap Assets
Assets
52272000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3343000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3425000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6306000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6555000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2120000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2778000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
352000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12174000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13426000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
15044000
CY2023Q4 us-gaap Other Liabilities And Deferred Revenue Noncurrent
OtherLiabilitiesAndDeferredRevenueNoncurrent
552000
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
306000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
237000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
610000
CY2022Q4 us-gaap Liabilities
Liabilities
30441000
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.1
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.1
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35060920
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35060920
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
34723046
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
34723046
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
35000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
35000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
250711000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
249024000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-238058000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
12688000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
21831000
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1317000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1029000
CY2023 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
12956000
CY2022 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
15301000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10087000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-8604000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-4649000
CY2023 us-gaap Interest Expense
InterestExpense
1640000
CY2022 us-gaap Interest Expense
InterestExpense
926000
CY2023 us-gaap Investment Income Interest
InvestmentIncomeInterest
231000
CY2022 us-gaap Investment Income Interest
InvestmentIncomeInterest
89000
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-837000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-92000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
63000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-10830000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-5549000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
25414000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1466000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-5549000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
21831000
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1303000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
12688000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-5549000
CY2023 us-gaap Depreciation And Amortization
DepreciationAndAmortization
5553000
CY2022 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
107000
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
1303000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
1466000
CY2023 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-72000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
603000
CY2023 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-197000
CY2022 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
229000
CY2023 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-472000
CY2022 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-644000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-519000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-924000
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5019000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4367000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1323000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-5791000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6795000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12586000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8118000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6795000
CY2023 us-gaap Interest Paid Net
InterestPaidNet
1415000
CY2022 us-gaap Interest Paid Net
InterestPaidNet
744000
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4440000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
312000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
231000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
355000
CY2023Q4 us-gaap Asset Acquisition Contingent Consideration Liability Current
AssetAcquisitionContingentConsiderationLiabilityCurrent
53000
CY2022Q4 us-gaap Asset Acquisition Contingent Consideration Liability Current
AssetAcquisitionContingentConsiderationLiabilityCurrent
313000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
7476000
CY2022Q4 us-gaap Other Liabilities And Deferred Revenue Noncurrent
OtherLiabilitiesAndDeferredRevenueNoncurrent
314000
CY2023Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
186000
CY2023Q4 us-gaap Asset Acquisition Contingent Consideration Liability Noncurrent
AssetAcquisitionContingentConsiderationLiabilityNoncurrent
1135000
CY2022Q4 us-gaap Asset Acquisition Contingent Consideration Liability Noncurrent
AssetAcquisitionContingentConsiderationLiabilityNoncurrent
8309000
CY2023Q4 us-gaap Liabilities
Liabilities
29328000
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-227228000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
52272000
CY2023 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
33358000
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
36161000
CY2023 us-gaap Cost Of Revenue
CostOfRevenue
14897000
CY2022 us-gaap Cost Of Revenue
CostOfRevenue
14393000
CY2023 us-gaap Gross Profit
GrossProfit
18461000
CY2022 us-gaap Gross Profit
GrossProfit
21768000
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10508000
CY2023 us-gaap Costs And Expenses
CostsAndExpenses
27065000
CY2022 us-gaap Costs And Expenses
CostsAndExpenses
26417000
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2318000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10922000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5486000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-10830000
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
5293000
CY2022 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
395000
CY2023 sskn Amortization Of Debt Issuance Costs And Debt Discount Premium
AmortizationOfDebtIssuanceCostsAndDebtDiscountPremium
140000
CY2022 sskn Amortization Of Debt Issuance Costs And Debt Discount Premium
AmortizationOfDebtIssuanceCostsAndDebtDiscountPremium
157000
CY2023 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-110000
CY2022 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-52000
CY2023 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-120000
CY2022 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
40000
CY2023 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-141000
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1145000
CY2023 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-689000
CY2022 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1340000
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-246000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
111000
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-100000
CY2023 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-376000
CY2022 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-477000
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5019000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6861000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-500000
CY2023 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
22000
CY2022 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
19000
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-style: normal; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: left;">Concentrations of Credit Risk and Major Customers</div> <div style="font-style: normal; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-family: 'Times New Roman';"><br/> </span> </div> <div style="display:none;"><br/></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold; text-indent: 36pt; text-align: left;"> <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The Company’s cash is held on deposit in demand accounts at a large financial institution in amounts in excess of the Federal Deposit Insurance Corporation, or FDIC, insurance coverage limit of $0.3 million per depositor, per FDIC-insured bank, per ownership category. Management has reviewed the financial statements of this institution and believes it has sufficient assets and liquidity to conduct its operations in the ordinary course of business with little credit risk to the Company. </span> </div> <div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="display:none;"><br/></div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-indent: 36pt; text-transform: none; text-align: left;">Financial instruments that potentially subject the Company to concentrations of credit risk principally consist of cash equivalents and accounts receivable. The Company limits its credit risk associated with cash equivalents by placing investments in highly-rated money market funds. The Company limits its credit risk with respect to accounts receivable by performing credit evaluations when deemed necessary, but it does not require collateral to secure amounts owed by its customers.</div> <div><span style="font-family: 'Times New Roman';"><br/> </span> </div> <div style="display:none;"><br/></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt; text-align: left;">The Company had one and two customers, international distributors, from which it earns dermatology recurring procedures and dermatology procedures equipment revenues, that accounted for 10% or more of the Company’s revenues for the years ended December 31, 2023 and 2022, respectively. Revenues from these customers were $3.3 million and $8.5 million, or 10% and 23%, of total net revenues during the years ended December 31, 2023 and 2022, respectively. Accounts receivable associated with these customers was <span style="-sec-ix-hidden:Fact_6b106dd2c6f64138869044d2c7b20499">nil</span> as of December 31, 2023 and $0.5 million, or 11%, of net accounts receivable as of December 31, 2022. One other customer had $0.7 million, or 16.5%, of net accounts receivable as of December 31, 2023. No other customer represented more than 10% of total accounts receivable as of December 31, 2022.</div>
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001051514
CY2023Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023 dei Auditor Firm
AuditorFirmId
688
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
0-11635
CY2023 dei Entity Registrant Name
EntityRegistrantName
STRATA SKIN SCIENCES, INC.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
13-3986004
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
5 Walnut Grove Drive
CY2023 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 140
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Horsham
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19044
CY2023 dei City Area Code
CityAreaCode
215
CY2023 dei Local Phone Number
LocalPhoneNumber
619-3200
CY2023 dei Security12b Title
Security12bTitle
Common Stock, $0.001 Par Value
CY2023 dei Trading Symbol
TradingSymbol
SSKN
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
17264756
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
35060920
CY2023 dei Auditor Name
AuditorName
Marcum LLP
CY2023 dei Auditor Location
AuditorLocation
Philadelphia, Pennsylvania
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6784000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
42016000
CY2023 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
2284000
CY2022 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2023 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-909000
CY2022 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.31
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.31
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.16
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34920291
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34920291
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34712246
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34712246
CY2022 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
500000
CY2023 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0
CY2023 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
384000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-10830000
CY2023 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
2284000
CY2022 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2023 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
349000
CY2023 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-909000
CY2022 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3736000
CY2023 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
0
CY2022 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
631000
CY2023 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
7000000
CY2022 us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
500000
CY2023 sskn Modification Of Common Stock Warrants
ModificationOfCommonStockWarrants
384000
CY2022 sskn Modification Of Common Stock Warrants
ModificationOfCommonStockWarrants
0
CY2022 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0
CY2023 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
97000
CY2022 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
0
CY2023 us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
42000
CY2023 sskn Transfer Of Property And Equipment To Inventories
TransferOfPropertyAndEquipmentToInventories
267000
CY2022 sskn Transfer Of Property And Equipment To Inventories
TransferOfPropertyAndEquipmentToInventories
463000
CY2023 sskn Change In Intangible Assets And Fair Value Of Contingent Consideration
ChangeInIntangibleAssetsAndFairValueOfContingentConsideration
7374000
CY2022 sskn Change In Intangible Assets And Fair Value Of Contingent Consideration
ChangeInIntangibleAssetsAndFairValueOfContingentConsideration
0
CY2023 sskn Accrued Exit Fee Recorded As Debt Discount
AccruedExitFeeRecordedAsDebtDiscount
450000
CY2022 sskn Accrued Exit Fee Recorded As Debt Discount
AccruedExitFeeRecordedAsDebtDiscount
0
CY2023 sskn Accrued Payment Of Contingent Consideration
AccruedPaymentOfContingentConsideration
18000
CY2022 sskn Accrued Payment Of Contingent Consideration
AccruedPaymentOfContingentConsideration
0
CY2023 us-gaap Noncash Or Part Noncash Acquisition Inventory Acquired1
NoncashOrPartNoncashAcquisitionInventoryAcquired1
0
CY2022 us-gaap Noncash Or Part Noncash Acquisition Inventory Acquired1
NoncashOrPartNoncashAcquisitionInventoryAcquired1
71000
CY2023 us-gaap Noncash Or Part Noncash Acquisition Intangible Assets Acquired1
NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
0
CY2022 us-gaap Noncash Or Part Noncash Acquisition Intangible Assets Acquired1
NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
10182000
CY2023 sskn Noncash Or Part Noncash Acquisition Contingent Consideration Issued In Connection With Asset
NoncashOrPartNoncashAcquisitionContingentConsiderationIssuedInConnectionWithAsset
0
CY2022 sskn Noncash Or Part Noncash Acquisition Contingent Consideration Issued In Connection With Asset
NoncashOrPartNoncashAcquisitionContingentConsiderationIssuedInConnectionWithAsset
9122000
CY2023 us-gaap Stock Issued1
StockIssued1
0
CY2022 us-gaap Stock Issued1
StockIssued1
500000
CY2023 sskn Change In Operating Lease Right Of Use Assets And Liability Due To New And Amended Lease
ChangeInOperatingLeaseRightOfUseAssetsAndLiabilityDueToNewAndAmendedLease
0
CY2022 sskn Change In Operating Lease Right Of Use Assets And Liability Due To New And Amended Lease
ChangeInOperatingLeaseRightOfUseAssetsAndLiabilityDueToNewAndAmendedLease
732000
CY2023 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="text-align: left; font-style: normal; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Reclassifications</div> <div style="text-align: left; font-style: normal; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br/> </div> <div style="display:none;"><br/></div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: left; text-indent: 36pt; text-transform: none;">Certain prior year amounts have been reclassified to conform to the current year presentation, including the reclassification of lasers-in-process from raw materials and work-in-process inventories and finished goods inventories to property and equipment, net on the consolidated balance sheet.</div>
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<div style="text-align: left; font-style: normal; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Use of Estimates</div> <div style="text-align: justify; font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span></div> <div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="display:none;"><br/></div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: left; text-indent: 36pt; text-transform: none;">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. The Company’s significant estimates and judgments include revenue recognition with respect to deferred revenues and the contract term and valuation allowances of accounts receivable, inputs used when evaluating goodwill for impairment, inputs used in the valuation of contingent consideration, state sales and use tax accruals, the estimated useful lives of intangible assets, and the valuation allowance related to deferred tax assets. Actual results could differ from those estimates.</div>
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6784000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5434000
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
1334000
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
1361000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8118000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6795000
CY2023 us-gaap Number Of Reporting Units
NumberOfReportingUnits
2
CY2023 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
2300000
CY2022 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2023 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2022 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2022Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
207000
CY2021Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
79000
CY2023 us-gaap Product Warranty Accrual Warranties Issued
ProductWarrantyAccrualWarrantiesIssued
237000
CY2022 us-gaap Product Warranty Accrual Warranties Issued
ProductWarrantyAccrualWarrantiesIssued
246000
CY2023 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
141000
CY2022 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
118000
CY2023Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
303000
CY2022Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
207000
CY2023Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
180000
CY2022Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
136000
CY2023Q4 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
123000
CY2022Q4 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
71000
CY2023 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
33358000
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
36161000
CY2023Q4 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
700000
CY2022Q4 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
600000
CY2023Q4 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
300000
CY2022Q4 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
400000
CY2023Q4 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2022Q4 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2023Q4 sskn Contract With Customer Liability Current Advance Consideration
ContractWithCustomerLiabilityCurrentAdvanceConsideration
300000
CY2022Q4 sskn Contract With Customer Liability Current Advance Consideration
ContractWithCustomerLiabilityCurrentAdvanceConsideration
400000
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
400000
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
200000
CY2023 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
400000
CY2022 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
900000
CY2023 us-gaap Advertising Expense
AdvertisingExpense
500000
CY2022 us-gaap Advertising Expense
AdvertisingExpense
1600000
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8551375
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5126344
CY2023 sskn Change In Operating Lease Right Of Use Assets And Liability Due To Amended Lease
ChangeInOperatingLeaseRightOfUseAssetsAndLiabilityDueToAmendedLease
700000
CY2022 sskn Change In Operating Lease Right Of Use Assets And Liability Due To Amended Lease
ChangeInOperatingLeaseRightOfUseAssetsAndLiabilityDueToAmendedLease
0
CY2023Q4 us-gaap Inventory Work In Process And Raw Materials
InventoryWorkInProcessAndRawMaterials
2192000
CY2022Q4 us-gaap Inventory Work In Process And Raw Materials
InventoryWorkInProcessAndRawMaterials
2966000
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
481000
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
129000
CY2023Q4 us-gaap Inventory Net
InventoryNet
2673000
CY2022Q4 us-gaap Inventory Net
InventoryNet
3095000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
36062000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
31906000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
24284000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
21956000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11778000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9950000
CY2023 us-gaap Depreciation
Depreciation
2900000
CY2022 us-gaap Depreciation
Depreciation
2400000
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
400000
CY2023 us-gaap Operating Lease Cost
OperatingLeaseCost
400000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
400000
CY2023 us-gaap Operating Lease Payments
OperatingLeasePayments
400000
CY2023 sskn Operating Lease Incremental Borrowing Rate Percent
OperatingLeaseIncrementalBorrowingRatePercent
0.086
CY2022 sskn Operating Lease Incremental Borrowing Rate Percent
OperatingLeaseIncrementalBorrowingRatePercent
0.0876
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y9M18D
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
386000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
195000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
55000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
636000
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
47000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
589000
CY2023Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
24222000
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
16903000
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
7319000
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
31596000
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
14202000
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
17394000
CY2023 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2700000
CY2022 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2900000
CY2023 sskn Asset Acquisition Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability
AssetAcquisitionContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability
7400000
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
1971000
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
1266000
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
561000
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
561000
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
561000
CY2023Q4 us-gaap Goodwill
Goodwill
6519000
CY2022Q4 us-gaap Goodwill
Goodwill
8803000
CY2023Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
180000
CY2022Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
136000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1679000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1997000
CY2023Q4 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
4316000
CY2022Q4 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
3986000
CY2023Q4 sskn Accrued Professional Fees Other Accrued Liabilities
AccruedProfessionalFeesOtherAccruedLiabilities
131000
CY2022Q4 sskn Accrued Professional Fees Other Accrued Liabilities
AccruedProfessionalFeesOtherAccruedLiabilities
436000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6306000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6555000
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
3750000
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
7500000
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
3750000
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
15000000
CY2023Q4 sskn Debt Instrument Exit Fee
DebtInstrumentExitFee
450000
CY2023Q4 sskn Long Term Debt After Exit Fee
LongTermDebtAfterExitFee
15450000
CY2023Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
406000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
15044000
CY2023Q1 sskn Litigation Settlement To Be Paid
LitigationSettlementToBePaid
100000
CY2023Q4 us-gaap Settlement Liabilities Current
SettlementLiabilitiesCurrent
100000
CY2023 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
400000
CY2022 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
300000
CY2023 sskn Development Agreement Term
DevelopmentAgreementTerm
P3Y
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023 us-gaap Stock Issued During Period Shares Restricted Stock Award Gross
StockIssuedDuringPeriodSharesRestrictedStockAwardGross
337874
CY2023 us-gaap Stock Issued During Period Shares Acquisitions
StockIssuedDuringPeriodSharesAcquisitions
358367
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1303000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1466000
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Accelerated Vesting Number
SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber
272098
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost
300000
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P7Y5M26D
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7458
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8957
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0438
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0251
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2022 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2023 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
28000
CY2022 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
23000
CY2023 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
28000
CY2022 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
23000
CY2023 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-68000
CY2022 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
23000
CY2023 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-52000
CY2022 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
17000
CY2023 us-gaap Deferred Federal State And Local Tax Expense Benefit
DeferredFederalStateAndLocalTaxExpenseBenefit
-120000
CY2022 us-gaap Deferred Federal State And Local Tax Expense Benefit
DeferredFederalStateAndLocalTaxExpenseBenefit
40000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-92000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
63000
CY2023Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
46718000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
45077000
CY2023Q4 sskn Deferred Tax Assets Intangible Assets
DeferredTaxAssetsIntangibleAssets
2138000
CY2022Q4 sskn Deferred Tax Assets Intangible Assets
DeferredTaxAssetsIntangibleAssets
1697000
CY2023Q4 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
71000
CY2022Q4 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
57000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
1381000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
1431000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
180000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
548000
CY2023Q4 sskn Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
145000
CY2022Q4 sskn Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
240000
CY2023Q4 sskn Deferred Tax Liabilities Interest Expense Limitation Carryover
DeferredTaxLiabilitiesInterestExpenseLimitationCarryover
552000
CY2022Q4 sskn Deferred Tax Liabilities Interest Expense Limitation Carryover
DeferredTaxLiabilitiesInterestExpenseLimitationCarryover
208000
CY2023Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
0
CY2022Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
1111000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
51185000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
50369000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
50139000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
49005000
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1046000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1364000
CY2023Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
412000
CY2022Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
0
CY2023Q4 sskn Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
154000
CY2022Q4 sskn Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
242000
CY2023Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Goodwill
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill
666000
CY2022Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Goodwill
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill
1095000
CY2023Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
0
CY2022Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
333000
CY2023Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1232000
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1670000
CY2023Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
186000
CY2022Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
306000
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
1100000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0018
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.0058
CY2023 sskn Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
-0.0189
CY2022 sskn Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
-0.0223
CY2023 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0807
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.112
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.1038
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.0814
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0084
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.0115
CY2023 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2
CY2023 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
33358000
CY2023 us-gaap Cost Of Revenue
CostOfRevenue
14897000
CY2023 us-gaap Gross Profit
GrossProfit
18461000
CY2023 sskn Percentage Of Gross Profit
PercentageOfGrossProfit
0.553
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1317000
CY2023 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
12956000
CY2023 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
2284000
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10508000
CY2023 us-gaap Costs And Expenses
CostsAndExpenses
27065000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-8604000
CY2023 us-gaap Interest Expense
InterestExpense
1640000
CY2023 us-gaap Investment Income Interest
InvestmentIncomeInterest
231000
CY2023 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-909000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10922000
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
36161000
CY2022 us-gaap Cost Of Revenue
CostOfRevenue
14393000
CY2022 us-gaap Gross Profit
GrossProfit
21768000
CY2022 sskn Percentage Of Gross Profit
PercentageOfGrossProfit
0.602
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1029000
CY2022 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
15301000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10087000
CY2022 us-gaap Costs And Expenses
CostsAndExpenses
26417000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-4649000
CY2022 us-gaap Interest Expense
InterestExpense
926000
CY2022 us-gaap Investment Income Interest
InvestmentIncomeInterest
89000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5486000
CY2023 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5553000
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5293000
CY2023 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
33358000
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
36161000
CY2023Q4 us-gaap Assets
Assets
42016000
CY2022Q4 us-gaap Assets
Assets
52272000

Files In Submission

Name View Source Status
0001140361-24-015754-index-headers.html Edgar Link pending
0001140361-24-015754-index.html Edgar Link pending
0001140361-24-015754.txt Edgar Link pending
0001140361-24-015754-xbrl.zip Edgar Link pending
ef20015284_10k.htm Edgar Link pending
ef20015284_ex10-26.htm Edgar Link pending
ef20015284_ex10-39.htm Edgar Link pending
ef20015284_ex23-1.htm Edgar Link pending
ef20015284_ex31-1.htm Edgar Link pending
ef20015284_ex31-2.htm Edgar Link pending
ef20015284_ex32-1.htm Edgar Link pending
ef20015284_ex4-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
ef20015284_10k_htm.xml Edgar Link completed
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
sskn-20231231.xsd Edgar Link pending
sskn-20231231_def.xml Edgar Link unprocessable
sskn-20231231_lab.xml Edgar Link unprocessable
sskn-20231231_pre.xml Edgar Link unprocessable
sskn-20231231_cal.xml Edgar Link unprocessable